Fluorescence-guided resection of tumors in mouse models of oral cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 07 2020
07 07 2020
Historique:
received:
08
02
2020
accepted:
18
05
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Complete removal and negative margins are the goal of any surgical resection of primary oral cavity carcinoma. Current approaches to determine tumor boundaries rely heavily on surgeons' expertise, and final histopathological reports are usually only available days after surgery, precluding contemporaneous re-assessment of positive margins. Intraoperative optical imaging could address this unmet clinical need. Using mouse models of oral cavity carcinoma, we demonstrated that PARPi-FL, a fluorescent PARP inhibitor targeting the enzyme PARP1/2, can delineate oral cancer and accurately identify positive margins, both macroscopically and at cellular resolution. PARPi-FL also allowed identification of compromised margins based on fluorescence hotspots, which were not seen in margin-negative resections and control tongues. PARPi-FL was further able to differentiate tumor from low-grade dysplasia. Intravenous injection of PARPi-FL has significant potential for clinical translation and could aid surgeons in assessing oral cancer margins in vivo.
Identifiants
pubmed: 32636416
doi: 10.1038/s41598-020-67958-8
pii: 10.1038/s41598-020-67958-8
pmc: PMC7341853
doi:
Substances chimiques
Fluorescent Dyes
0
Poly(ADP-ribose) Polymerase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11175Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : K99 CA218875
Pays : United States
Organisme : NCI NIH HHS
ID : R43 CA228815
Pays : United States
Références
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
pubmed: 30620402
Hillbertz, N. S. et al. Viral and molecular aspects of oral cancer. Anticancer Res. 32(10), 4201–4212 (2012).
pubmed: 23060540
Mignogna, M. D., Fedele, S. & Lo Russo, L. The World Cancer Report and the burden of oral cancer. Eur. J. Cancer Prev. 13(2), 139–142 (2004).
pubmed: 15100581
Fedele, S. Diagnostic aids in the screening of oral cancer. Head Neck Oncol. 1, 5 (2009).
pubmed: 19284694
pmcid: 2654034
Patel, S. C. et al. Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J. Clin. Oncol. 29(11), 1488–1494 (2011).
pubmed: 21383286
Zanoni, D. K. et al. A proposal to redefine close surgical margins in squamous cell carcinoma of the oral tongue. JAMA Otolaryngol. Head Neck Surg. 143(6), 555–560 (2017).
pubmed: 28278337
pmcid: 5473778
Shapiro, M. & Salama, A. Margin analysis: Squamous cell carcinoma of the oral cavity. Oral Maxillofac. Surg. Clin. North Am. 29(3), 259–267 (2017).
pubmed: 28709529
Looser, K. G., Shah, J. P. & Strong, E. W. The significance of “positive” margins in surgically resected epidermoid carcinomas. Head Neck Surg. 1(2), 107–111 (1978).
pubmed: 755803
Rajapakshe, R. M. et al. A retrospective analysis to determine factors contributing to the survival of patients with oral squamous cell carcinoma. Cancer Epidemiol. 39(3), 360–366 (2015).
pubmed: 25779678
Bernier, J. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350(19), 1945–1952 (2004).
pubmed: 15128894
Cooper, J. S. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350(19), 1937–1944 (2004).
pubmed: 15128893
Potts, M. M. E. Choices: The Most Complete Sourcebook for Cancer Information 4th edn, 1113 (HarperResource, New York, 2003).
Du, E. et al. Refining the utility and role of frozen section in head and neck squamous cell carcinoma resection. Laryngoscope 126(8), 1768–1775 (2016).
pubmed: 27113207
Kain, J. J. et al. Surgical margins in oral cavity squamous cell carcinoma: Current practices and future directions. Laryngoscope 130, 128–138 (2019).
pubmed: 31025711
Kossatz, S. et al. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. Sci. Rep. 6, 21371 (2016).
pubmed: 26900125
pmcid: 4761964
Thurber, G. M. et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat. Commun. 4, 1504 (2013).
pubmed: 23422672
pmcid: 3579506
Carney, B., Kossatz, S. & Reiner, T. Molecular imaging of PARP. J. Nucl. Med. 58(7), 1025–1030 (2017).
pubmed: 28473593
pmcid: 5493005
Kossatz, S. et al. Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nat. Biomed. Eng. 4(3), 272–285 (2020).
pubmed: 32165735
Carney, B., Kossatz, S. & Reiner, T. Molecular Imaging of PARP. J Nucl Med 58(7), 1025–1030 (2017).
pubmed: 28473593
pmcid: 5493005
Reiner, T. et al. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 14(3), 169–177 (2012).
pubmed: 22496617
pmcid: 3323895
Dubach, J. M. et al. In vivo imaging of specific drug-target binding at subcellular resolution. Nat Commun 5, 3946 (2014).
pubmed: 24867710
pmcid: 4362617
Dubach, J. M. et al. Quantitating drug-target engagement in single cells in vitro and in vivo. Nat. Chem. Biol. 13(2), 168–173 (2017).
pubmed: 27918558
Carney, B. et al. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nat. Commun. 9(1), 176 (2018).
pubmed: 29330466
pmcid: 5766608
Demetrio de Souza Franca, P. et al. Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography in oral cancer imaging. Nucl. Med. Biol. 84–85, 80–87 (2020).
pubmed: 32135475
Kossatz, S., Weber, W. A. & Reiner, T. Optical imaging of PARP1 in response to radiation in oral squamous cell carcinoma. PLoS ONE 11(1), e0147752 (2016).
pubmed: 26808835
pmcid: 4726809
Chow, J. P. et al. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol. Cancer Ther. 12(11), 2517–2528 (2013).
pubmed: 23979918
Slooter, M. D. et al. Detecting tumour-positive resection margins after oral cancer surgery by spraying a fluorescent tracer activated by gamma-glutamyltranspeptidase. Oral Oncol. 78, 1–7 (2018).
pubmed: 29496035
Scott-Wittenborn, N. & Jackson, R. S. Intraoperative imaging during minimally invasive transoral robotic surgery using near-infrared light. Am. J. Otolaryngol. 39(2), 220–222 (2018).
pubmed: 29128262
Christensen, A. et al. uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: Proof-of-concept in orthotopic xenograft model. Oncotarget 8(9), 15407–15419 (2017).
pubmed: 28039488
Gao, R. W. et al. Determination of tumor margins with surgical specimen mapping using near-infrared fluorescence. Cancer Res. 78(17), 5144–5154 (2018).
pubmed: 29967260
pmcid: 6125224
Fatima, S., Basu, R. & Hallur, N. H. Lugol’s iodine identifies dysplastic tissue in precancerous lesions: A clinical trial. Ann. Maxillofac. Surg. 6(2), 172–174 (2016).
pubmed: 28299253
pmcid: 5343623
Junaid, M. et al. A comparative analysis of toluidine blue with frozen section in oral squamous cell carcinoma. World J. Surg. Oncol. 10, 57 (2012).
pubmed: 22500814
pmcid: 3349537
Prabhu, A. V. et al. Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. Oral Oncol. 75, 184–188 (2017).
pubmed: 29074194
pmcid: 5774620
Johnson, R. E. et al. Quantification of surgical margin shrinkage in the oral cavity. Head Neck 19(4), 281–286 (1997).
pubmed: 9213106
Thurber, G. M. et al. Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors. Mol. Cancer Ther. 13(4), 986–995 (2014).
pubmed: 24552776
pmcid: 3981972
Kossatz, S. et al. PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers—First-in-human results 663385. bioRxiv (2019).
Irwin, C. P. et al. PARPi-FL—A fluorescent PARP1 inhibitor for glioblastoma imaging. Neoplasia 16(5), 432–440 (2014).
pubmed: 24970386
pmcid: 4198695
Carlucci, G. et al. Dual-modality optical/PET imaging of PARP1 in glioblastoma. Mol. Imaging Biol. 17(6), 848–855 (2015).
pubmed: 25895168
pmcid: 4609241
Sopka, D. M. et al. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘low-risk’ squamous cell carcinoma of the oral tongue. Oral Oncol. 49(11), 1083–1087 (2013).
pubmed: 24054332
pmcid: 4037753
Chen, T. C. et al. Impact of dysplastic surgical margins for patients with oral squamous cell carcinoma. Oral Oncol. 97, 1–6 (2019).
pubmed: 31421465
Tada, M., Kohda, K. H. & Kawazoe, Y. Biomimetic preparation and structure determination of QGI, one of the quinoline-DNA base adducts formed in cells treated with 4-nitroquinoline 1-oxide. Gan 75(11), 976–985 (1984).
pubmed: 6097493
Steidler, N. E. & Reade, P. C. Experimental induction of oral squamous cell carcinomas in mice with 4-nitroquinolone-1-oxide. Oral Surg. Oral Med. Oral Pathol. 57(5), 524–531 (1984).
pubmed: 6427721
Kanojia, D. & Vaidya, M. M. 4-Nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol. 42(7), 655–667 (2006).
pubmed: 16448841
Li, J. et al. Development of a 4-nitroquinoline-1-oxide model of lymph node metastasis in oral squamous cell carcinoma. Oral Oncol. 49(4), 299–305 (2013).
pubmed: 23187306
Zhou, Y. & Kreek, M. J. Combination of clinically utilized kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice. Alcohol Clin. Exp. Res. 43, 1077–1090 (2019).
pubmed: 30908671
pmcid: 6551307
Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18(9), 1274–1284 (2017).
pubmed: 28754483
Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379(26), 2495–2505 (2018).
pubmed: 30345884
Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22(3), 659–661 (2008).
pubmed: 17942826
Rangan, S. R. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29(1), 117–121 (1972).
pubmed: 4332311
Jiang, L. et al. CAL 27 is an oral adenosquamous carcinoma cell line. Oral Oncol. 45(11), e204–e207 (2009).
pubmed: 19631575
Gioanni, J. et al. Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: Establishment, characterization and response to cytotoxic treatment. Eur. J. Cancer Clin. Oncol. 24(9), 1445–1455 (1988).
pubmed: 3181269
Hawkins, B. L. et al. 4NQO carcinogenesis: A mouse model of oral cavity squamous cell carcinoma. Head Neck 16(5), 424–432 (1994).
pubmed: 7960739